OraSure Technologies Stock Forecast, Price & News

+0.38 (+3.37 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume909,353 shs
Average Volume1.01 million shs
Market Capitalization$839.77 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OraSure Technologies logo

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.73 out of 5 stars

Medical Sector

641st out of 2,214 stocks

Surgical & Medical Instruments Industry

64th out of 185 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

Is OraSure Technologies a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OraSure Technologies stock.
View analyst ratings for OraSure Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than OraSure Technologies?

Wall Street analysts have given OraSure Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OraSure Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for OraSure Technologies

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) issued its quarterly earnings results on Wednesday, May, 5th. The medical instruments supplier reported $0.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.02. The medical instruments supplier had revenue of $58.58 million for the quarter, compared to the consensus estimate of $58.07 million. OraSure Technologies had a negative trailing twelve-month return on equity of 0.97% and a negative net margin of 1.92%.
View OraSure Technologies' earnings history

How has OraSure Technologies' stock price been impacted by COVID-19?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OSUR stock has increased by 97.8% and is now trading at $11.67.
View which stocks have been most impacted by COVID-19

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $55 million-$60 million, compared to the consensus revenue estimate of $66.98 million.

What price target have analysts set for OSUR?

5 analysts have issued 1-year price targets for OraSure Technologies' stock. Their forecasts range from $11.00 to $22.00. On average, they anticipate OraSure Technologies' stock price to reach $17.40 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts' price targets for OraSure Technologies
or view top-rated stocks among Wall Street analysts.

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 60, Pay $1.87M)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 53, Pay $937.09k)
  • Mr. Jack E. Jerrett, Sr. VP, Chief Compliance Officer, Gen. Counsel & Sec. (Age 62, Pay $706.79k)
  • Ms. Kathleen Gallagher Weber, Exec. VP & Bus. Unit Leader of Molecular Solutions (Age 54, Pay $1.12M)
  • Ms. Lisa Nibauer, Exec. VP & Bus. Unit Leader of Diagnostics (Age 53, Pay $554.85k)
  • Mr. Scott Gleason, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Michele Marie Miller, VP of Fin., Controller & Assistant Sec. (Age 47)

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies CEO Stephen Tang on Stephen Tang has an approval rating of 100% among OraSure Technologies' employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%).
View institutional ownership trends for OraSure Technologies

Which major investors are buying OraSure Technologies stock?

OSUR stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for OraSure Technologies
or or view top insider-buying stocks.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $11.67.

How much money does OraSure Technologies make?

OraSure Technologies has a market capitalization of $839.77 million and generates $171.72 million in revenue each year. The medical instruments supplier earns $-14,920,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does OraSure Technologies have?

OraSure Technologies employs 570 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is

Where are OraSure Technologies' headquarters?

OraSure Technologies is headquartered at 220 EAST FIRST STREET, BETHLEHEM PA, 18015.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.